Definitive Contract HHSN272201300015C
Award Date
9/16/13
Potential Completion Date
1/15/16
Potential Value
$225K
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Pulmokine, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Slingerlands, NY 12159, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
<p>This is a $225,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Windtree Therapeutics, Inc. under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development of a "K4L SURFACTANT AEROSOL TO REDUCE INFLUENZA LUNG INJURY" and has an ultimate completion date of December 31, 2016. The contract is designated as a Total Small Business set-aside.</p>
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Qrumpharma, Inc., a self-certified small disadvantaged business, for a Small Business Innovation Research (SBIR) Program Phase I project. The objective is to determine the feasibility of a clofazimine inhalation formulation for preclinical development in tuberculosis. The contract is a definitive contract with a firm...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
This is a purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the National Institute For Research In Tuberculosis, a non-profit organization that operates as a hospital. The $537,500.00 firm fixed price award is to provide support to conduct studies on tuberculosis in India. The contract has a performance period ending on May 31, 2019 and was awarded on November 30, 2015. No set-aside was used for this contract. The National...